Core Viewpoint - Capbio reported a significant decline in revenue and an increase in net loss for the first three quarters of 2025 compared to the previous year [1] Financial Performance - The company's operating revenue for the first three quarters was 486 million yuan, representing a year-on-year decrease of 20.38% [1] - The net loss attributable to shareholders of the listed company was 128 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 135 million yuan [1] - The basic loss per share was 0.1996 yuan [1]

Core Viewpoint - Capbio reported a significant decline in revenue and an increase in net loss for the first three quarters of 2025, indicating financial challenges for the company [1] Financial Performance - The company's operating revenue for the first three quarters was 486 million yuan, a year-on-year decrease of 20.38% [1] - The net loss attributable to shareholders was 128 million yuan [1] - The net loss attributable to shareholders, excluding non-recurring gains and losses, was 135 million yuan [1] - The basic loss per share was 0.1996 yuan [1]

证券代码：300639 证券简称：凯普生物 公告编号：2025-061 广东凯普生物科技股份有限公司 2023 年 3 月 31 日，为加快项目推进，保障项目建设资金及时到位，公司召 开第五届董事会第五次会议和第五届监事会第四次会议，审议通过了《关于全资 子公司申请银团贷款及公司为其提供担保的议案》，同意公司全资子公司凯普医 学产业向银团申请贷款专用于凯普医学科学园建设项目，由凯普医学产业以其持 有的"凯普医学科学园建设项目"土地使用权及其上拟建建筑物提供抵押担保， 并由公司为其提供连带责任担保及以公司持有的凯普医学产业的股权作质押担 保，以及运营凯普医学科学园建设项目各子项目的集团成员企业提供连带责任担 保。上述议案已经公司 2023 年第一次临时股东大会审议通过。 2023 年 5 月，凯普医学产业与银团签署了《凯普医学科学园建设项目人民 币资金银团贷款合同》及《凯普医学科学园建设项目银团抵押合同》；公司与银 团签署了《凯普医学科学园建设项目银团保证合同》及《凯普医学科学园建设项 目银团质押合同》。详见公司 2023 年 5 月 9 日在巨潮资讯网披露的《关于全资 子公司申请银团贷款及公司为其提供担保的进 ...

广东凯普生物科技股份有限公司（以下简称"公司"）于2025年10月28日召 开第六届董事会第三次会议审议通过了《关于2025年前三季度计提资产减值准备 的议案》。根据《深圳证券交易所上市公司自律监管指引第2号——创业板上市 公司规范运作》等相关法律法规的规定，现将本次计提资产减值的具体情况公告 如下： 一、本次计提信用减值和资产减值准备概述 公司根据《企业会计准则》《深圳证券交易所创业板股票上市规则》及公司 会计政策的相关规定，基于谨慎性原则，公司对合并报表范围内截至 2025 年 9 月 30 日的应收账款、其他应收款、存货、固定资产、其他非流动资产等各类资 产进行了全面清查，对各项资产减值的可能性进行了充分的评估和分析，对存在 减值迹象的资产计提相应减值准备。 公司 2025 年前三季度计提信用减值和资产减值的资产项目主要是应收账款、 其他应收款、存货、固定资产、预付账款；其中，计提信用减值损失 79,333,119.27 元，计提资产减值损失 10,437,663.57 元。 | | 计提项目 | 2025 年前三季度发生额 | | --- | --- | --- | | | | （元） | | 1、信 ...

广东凯普生物科技股份有限公司（以下简称"公司"）第六届董事会第三次会 议于 2025 年 10 月 24 日以电子邮件、电话通讯等形式发出通知。本次会议于 2025 年 10 月 28 日 10:00 在广东省潮州市经济开发试验区北片高新区 D5-3-3-4 小区公司 会议室通过现场表决和通讯表决相结合的方式召开。本次会议应出席董事 9 名，实 际出席董事 9 名。公司高级管理人员列席了本次会议。会议由董事长管乔中先生主 持。会议的召集和召开符合《中华人民共和国公司法》等法律法规及《公司章程》 的规定。 二、董事会会议审议情况 1、审议通过了《关于 2025 年前三季度计提资产减值准备的议案》； 公司依照《企业会计准则》及公司会计政策的相关规定，对合并范围内截至 2025 年 9 月 30 日的各类资产进行全面清查、评估和分析。经资产减值测试，判断部分 资产存在一定的减值迹象。本着谨慎性原则，同意公司对可能发生资产减值损失的 相关资产计提减值准备共计人民币 89,770,782.84 元。本次计提资产减值准备依据 充分，计提后能客观、真实、公允地反应公司的资产状况。具体内容详见公司同日 在巨潮资讯网（http ...

Financial Performance - The company's operating revenue for Q3 2025 was ¥170,878,580.77, a decrease of 15.14% compared to the same period last year[5] - The net profit attributable to shareholders was -¥38,091,900.98, representing an increase in loss of 79.41% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -¥39,779,349.67, an increase in loss of 78.44% year-on-year[5] - The company achieved total operating revenue of CNY 48,587.17 million, representing a year-on-year decline of 20.38%[17] - The net profit attributable to shareholders was -CNY 12,768.33 million, with a year-on-year loss reduction of 51.25%[17] - The company reported a net profit attributable to shareholders after deducting non-recurring gains and losses of -CNY 13,538.97 million, a 49.89% reduction in loss compared to the previous year[17] - Operating profit showed a loss of ¥170.83 million, an improvement from a loss of ¥456.83 million in the previous period[28] - Net profit loss narrowed to ¥189.38 million compared to a loss of ¥400.72 million in the same period last year, indicating a 52.8% improvement[28] - The company reported a total comprehensive loss of ¥226.52 million, compared to a loss of ¥407.28 million in the previous period, showing a 44.3% improvement[29] Cash Flow and Assets - The cash flow from operating activities for the year-to-date was ¥121,210,400.21, an increase of 173.06%[5] - The company reported a net cash flow from operating activities of CNY 12,121.04 million for the first nine months of 2025, a 173.06% increase compared to CNY 4,438.94 million in the same period of 2024, primarily due to reduced salary and tax payments[13] - The company experienced a net cash flow from investing activities of -CNY 2,515.14 million, a significant decrease of 114.98% from CNY 16,794.77 million in the previous year, mainly due to increased purchases of financial products[13] - The net increase in cash and cash equivalents was CNY 2,267.13 million, down 84.31% from CNY 14,453.46 million in the prior year, attributed to increased investments in financial products[13] - Cash flow from operating activities generated ¥121.21 million, a significant increase from ¥44.39 million in the previous period[31] - Cash and cash equivalents at the end of the period totaled ¥684.79 million, down from ¥905.90 million year-over-year[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,282,405,863.85, a decrease of 7.37% from the end of the previous year[5] - The total assets as of September 30, 2025, amounted to CNY 4,282,405,863.85, a decrease from CNY 4,622,985,300.71 at the beginning of the period[24] - The total liabilities as of September 30, 2025, were CNY 553,762,084.98, down from CNY 576,437,152.67 at the beginning of the period[25] - The company's current assets totaled CNY 1,976,063,479.06, a decrease from CNY 2,225,642,938.29 at the beginning of the period[24] - The company's non-current assets amounted to CNY 2,306,342,384.79, down from CNY 2,397,342,362.42 at the beginning of the period[24] - The company's cash and cash equivalents decreased to CNY 696,757,930.99 from CNY 712,357,379.26 at the beginning of the period[23] - The company's inventory increased to CNY 79,475,140.68 from CNY 65,662,916.94 at the beginning of the period[24] Operational Developments - The company has developed a new respiratory pathogen nucleic acid testing kit, which received a Class III medical device registration certificate from the National Medical Products Administration[18] - The company is focusing on enhancing the operational quality and efficiency of its "Kepu Kang and Medical Testing 5.0 Project" to improve revenue from high-value projects and reduce operational costs[17] - The company plans to strengthen the collection of accounts receivable and optimize its medical testing laboratory business to increase revenue from high-margin projects[17] - The company has obtained a total of 98 medical device registration certificates, including 35 Class III medical device registration certificates, and 59 CE certifications, with 26 under the new EU Medical Device Regulation IVDR[19] - The company has accumulated 219 patent authorizations, including 130 domestic and international invention patents, with 12 new invention patents authorized during the reporting period[19] Governance and Management - The company completed the adjustment of its governance structure and the election of the sixth board of directors, enhancing its operational standards[20] - The company has appointed a new board of directors and senior management during the first extraordinary shareholders' meeting held on September 10, 2025[21] Accounting and Reporting - The third quarter financial report of Guangdong Cape Biotechnology Co., Ltd. has not been audited[33] - The new accounting standards will be implemented starting from 2025, affecting the financial statements from the beginning of that year[32]

Group 1 - The core viewpoint of the news is that Capbio has experienced fluctuations in its stock price and financial performance, with a recent increase in stock price but a decline in revenue and profit for the first half of 2025 [1][2]. Group 2 - As of October 21, Capbio's stock price rose by 2.15% to 5.71 CNY per share, with a total market capitalization of 3.692 billion CNY [1]. - Year-to-date, Capbio's stock price has decreased by 3.71%, with a 2.33% increase over the last five trading days, but a decline of 3.38% over the last 20 days and 10.78% over the last 60 days [1]. - The company reported a revenue of 315 million CNY for the first half of 2025, a year-on-year decrease of 22.96%, and a net profit of -89.59 million CNY, a year-on-year decrease of 16.46% [2]. - Capbio's main business revenue composition includes 67.58% from self-produced products, 30.89% from inspection services, and 1.53% from other sources [1]. - The company has distributed a total of 485 million CNY in dividends since its A-share listing, with 193 million CNY distributed in the last three years [3].

Core Points - The company announced that it will hold the sixth board meeting on October 13, 2025, to review a proposal regarding the use of raised funds to replace self-owned funds that were previously used to pay personnel costs for investment projects [2] Summary by Category - **Company Actions** - The company plans to use raised funds amounting to 9,390,908.85 yuan to replace self-owned funds that were pre-paid for personnel costs related to investment projects [2]

中信证券股份有限公司 关于广东凯普生物科技股份有限公司 使用募集资金置换自有资金预先支付的 募投项目人员费用的核查意见 中信证券股份有限公司（以下简称"中信证券""保荐机构"）作为广东凯普生物科 技股份有限公司（以下简称"凯普生物""公司"）的保荐机构，根据《证券发行上 市保荐业务管理办法》《上市公司监管指引第2号——上市公司募集资金管理和使用的 监管要求》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第2号——创业板上市公司规范运作》等相关规定履行持续督导职责，对凯普 生物使用募集资金置换自有资金预先支付的募投项目人员费用的事项进行了审慎核查， 核查情况及核查意见如下： 一、募集资金基本情况 2025年3月19日，公司召开第五届董事会第二十七次会议和第五届监事会第二十次 会议，审议通过了《关于使用自有资金支付募投项目人员费用并以募集资金等额置换 的议案》，在不影响募投项目正常实施的前提下，同意使用自有资金支付募投项目人 员费用，后续以募集资金等额置换，定期从募集资金专户划转等额资金至公司非募集 资金账户，该部分等额置换资金视同募投项目使用资金，上述事项无需提交公司股东 大会审议， ...

Core Viewpoint - Capbio (SZ 300639) announced the convening of its sixth second board meeting on October 13, 2025, to discuss various proposals, including providing guarantees for its wholly-owned subsidiary and replacing some collateral under a syndicated loan [1] Financial Performance - For the first half of 2025, Capbio's revenue composition was as follows: molecular diagnostic products accounted for 67.65%, medical testing services for 29.07%, and medical service income for 3.27% [1] Market Position - As of the report, Capbio's market capitalization stood at 3.6 billion yuan [1]